The clinical implication of changing unbound quinidine levels

Kenneth M. Kessler, Paula M. Wozniak, Daneil McAuliffe, Elizabeth Terracall, Patricia Kozlovskis, Imrana Mahmood, Liaqat Zaman, Richard G. Trohman, Augustin Castellanos, Robert J. Myerburg

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Pharmacodynamic and pharmacokinetic aspects pertinent to the potential clinical application of unbound quinidine levels were studied. Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (± SD) right ventricular effective refractory period (266 ± 24 versus 279 ± 23; p < 0.025), free fatty acid concentration (515 ± 213 versus 1071 ± 359 mmol/L; p < 0.001), and unbound quinidine concentration (0.3 ± 0.1 to 0.6 ± 0.1 μg/ml; p < 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration. Ten control patients showed no change in the right ventricular effective refractory period following heparin administration. These findings were consistent with a heparin-induced increase in unbound drug concentration and activity that was limited to the vascular compartment. Eleven patients studied on day 3 (±1) and day 10 (±3) during an acute myocardial infarction showed a significant decrease in unbound quinidine fraction (12 ± 4% versus 9 ± 4%; p < 0.02) accompanied by a decrease, rather than the predicted increase, in half-life (7.1 ± 2.7 versus 6.3 ± 2.1 hours; p < 0.02). Volumes of distribution remained stable while the mean quinidine clearance tended to increase. Half-life correlated with albumin changes (r = -0.71; p < 0.02). Apparently, improvement in clinical status (assumed) and drug clearance (measured) negated the direct effects of the decrease in unbound quinidine fraction. Although unbound drug concentrations should correlate best with drug dynamic and kinetic information, full knowledge of the clinical context of such measurements is needed for appropriate interpretation.

Original languageEnglish (US)
Pages (from-to)63-69
Number of pages7
JournalAmerican Heart Journal
Volume118
Issue number1
DOIs
StatePublished - Jul 1989

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The clinical implication of changing unbound quinidine levels'. Together they form a unique fingerprint.

  • Cite this

    Kessler, K. M., Wozniak, P. M., McAuliffe, D., Terracall, E., Kozlovskis, P., Mahmood, I., Zaman, L., Trohman, R. G., Castellanos, A., & Myerburg, R. J. (1989). The clinical implication of changing unbound quinidine levels. American Heart Journal, 118(1), 63-69. https://doi.org/10.1016/0002-8703(89)90073-2